These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33677052)

  • 61. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.
    Brock PR; Knight KR; Freyer DR; Campbell KC; Steyger PS; Blakley BW; Rassekh SR; Chang KW; Fligor BJ; Rajput K; Sullivan M; Neuwelt EA
    J Clin Oncol; 2012 Jul; 30(19):2408-17. PubMed ID: 22547603
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma.
    Guillaume DJ; Knight K; Marquez C; Kraemer DF; Bardo DM; Neuwelt EA
    J Neurosurg Pediatr; 2012 Apr; 9(4):421-7. PubMed ID: 22462709
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
    Jalali MM; Saedi HS; Saadat F
    Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Radiation dose to the cochlea and its association with sensorineural hearing loss in head and neck cancer-A prospective study.
    Apoorva KV; Vijendra Shenoy S; Athiyamaan MS; Kabekkodu S; Kshithi K; Zuturu N
    Am J Otolaryngol; 2023; 44(4):103914. PubMed ID: 37178536
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
    Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
    Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1.
    Turan C; Kantar M; Aktan Ç; Kosova B; Orman M; Bilgen C; Kirazlı T
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1333-1338. PubMed ID: 31586226
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma.
    Polkinghorn WR; Dunkel IJ; Souweidane MM; Khakoo Y; Lyden DC; Gilheeney SW; Becher OJ; Budnick AS; Wolden SL
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e15-20. PubMed ID: 21481547
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer.
    Schuette A; Lander DP; Kallogjeri D; Collopy C; Goddu S; Wildes TM; Daly M; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Feb; 146(2):106-112. PubMed ID: 31750863
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
    Clemens E; Broer L; Langer T; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Byrne J; Broeder EVD; Crocco M; Grabow D; Kaatsch P; Kaiser M; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Kuehni CE; van der Pal H; Parfitt R; Deuster D; Matulat P; Spix C; Tillmanns A; Tissing WJE; Maier L; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM;
    Pharmacogenomics J; 2020 Apr; 20(2):294-305. PubMed ID: 31666714
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.
    Sanchez VA; Dinh PC; Monahan PO; Althouse S; Rooker J; Sesso HD; Dolan ME; Weinzerl M; Feldman DR; Fung C; Einhorn LH; Frisina RD; Travis LB
    JAMA Oncol; 2024 Jul; 10(7):912-922. PubMed ID: 38842797
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Asymmetric sensorineural hearing loss is a risk factor for late-onset hearing loss in pediatric cancer survivors following cisplatin treatment.
    Robertson MS; Hayashi SS; Camet ML; Trinkaus K; Henry J; Hayashi RJ
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27494. PubMed ID: 30334605
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system.
    Stöhr W; Langer T; Kremers A; Bielack S; Lamprecht-Dinnesen A; Frey E; Beck JD;
    Cancer Invest; 2005; 23(3):201-7. PubMed ID: 15945505
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Feasibility and first results of a prospective cohort study to investigate cisplatin-associated ototoxicity amongst cancer patients in South Africa.
    Paken J; Govender CD; Pillay M; Ayele BT; Sewram V
    BMC Cancer; 2021 Jul; 21(1):822. PubMed ID: 34271863
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
    Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Risk factors for hearing loss in patients treated with intensity-modulated radiotherapy for head-and-neck tumors.
    Zuur CL; Simis YJ; Lamers EA; Hart AA; Dreschler WA; Balm AJ; Rasch CR
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):490-6. PubMed ID: 19135315
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Transient Receptor Potential Channels and Auditory Functions.
    Ramkumar V; Sheth S; Dhukhwa A; Al Aameri R; Rybak L; Mukherjea D
    Antioxid Redox Signal; 2022 Jun; 36(16-18):1158-1170. PubMed ID: 34465184
    [No Abstract]   [Full Text] [Related]  

  • 77. Audiological profile of patients treated for childhood cancer.
    Liberman PH; Goffi-Gomez MV; Schultz C; Novaes PE; Lopes LF
    Braz J Otorhinolaryngol; 2016; 82(6):623-629. PubMed ID: 27156673
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Incidence and Risk Factors of Cisplatin and Carboplatin Ototoxicity in Pediatric Oncology Patients at Tertiary Oncology Center.
    Attar M; Alqarni MS; Alsinnari YM; Bukhari ZM; Alshegifi H; Alzhrani A; Alshaikh K; Alsubaie H; Muqat M; Alhakami H; Algarni M
    Indian J Surg Oncol; 2022 Dec; 13(4):925-930. PubMed ID: 36687225
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study.
    Weiss A; Sommer G; Kasteler R; Scheinemann K; Grotzer M; Kompis M; Kuehni CE;
    Pediatr Blood Cancer; 2017 Feb; 64(2):364-373. PubMed ID: 27650356
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
    Moore B; Sheets G; Doss J; Umrigar A; Norman M; Fang Z; Prasad P; Musso A; Clay S; Tsien F
    Am J Audiol; 2023 Sep; 32(3):657-664. PubMed ID: 37532243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.